Lexington Engages with Major Canadian University and Provides Clinical Trial Update

Lexington Biosciences (CSE:LNB) (OTCQB:LXGTF) a development-stage medical device company, is pleased to advise it has engaged with a dedicated research team at The University of British Columbia to perform an independent analysis and validation of the investigative data generated during the course of our clinical study currently underway in California.

As quoted in the press release:

Founded in 1915, the University of British Columbia is a global centre for research and teaching, consistently ranked among the top 20 public universities in the world. With two main campuses, an annual operating budget of $2.5 billion brings together over 15,000 faculty and staff serving more than 60,000 students.

Lexington’s President Eric Willis notes, “As we move through the various phases of our clinical research project, the data generated by the San Francisco Bay-area Diablo Clinical Research group will undergo further analysis as a part of our commitment to scientific validity and regulatory compliance. Accordingly, we are pleased to have enlisted the expertise of the UBC cardiology research group and look forward to working with them on this project. We are excited about the potential of establishing a long-term collaboration with UBC and the broader Canadian medical research community. Additionally, we are pleased to report that our pilot clinical study at Diablo is proceeding according to plan and we are enrolling patients in the second phase of the pilot study to continue to build statistical support for HeartSentry’s endothelial function diagnosis capabilities.”

Click here to read the full press release.